Stockscreener 앱 받기
1.66
4.06%
0.06
시간 외 거래:
1.67
0.01
+0.60%
전일 마감가:
$1.60
열려 있는:
$1.6
하루 거래량:
707.69K
Relative Volume:
0.39
시가총액:
$382.34M
수익:
$8.95M
순이익/손실:
$-21.49M
주가수익비율:
-13.83
EPS:
-0.12
순현금흐름:
$-29.24M
1주 성능:
-0.89%
1개월 성능:
-5.40%
6개월 성능:
+83.49%
1년 성능:
+231.34%
1일 변동 폭
$1.58
$1.675
1주일 범위
$1.575
$1.68
52주 변동 폭
$0.3651
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
명칭
Lineage Cell Therapeutics Inc
전화
510-871-4188
주소
2173 Salk Avenue, Suite 200, Carlsbad, CA
LCTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.66 | 368.52M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Craig Hallum | Buy |
| 2022-11-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-14 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Noble Capital Markets | Outperform |
| 2021-03-31 | 개시 | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Cell Therapy Manufacturing Market Forecast Through 2032 - openPR.com
Lineage Cell Therapeutics: Progress Amid Financial Challenges - MSN
EBIT per share of Lineage Cell Therapeutics, Inc. – DUS:BT3 - TradingView — Track All Markets
Q3 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Is Lineage Cell Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Chart Watch & Safe Capital Allocation Plans - Улправда
Is Lineage Cell Therapeutics Inc. stock trading at a premium valuation2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Aug Wrap: Can Lineage Cell Therapeutics Inc. stock surprise with earnings upsideWeekly Gains Report & Daily Momentum Trading Reports - Улправда
Lineage Cell Therapeutics (LCTX) officer reports RSU vesting and tax share withholding - Stock Titan
Can Lineage Cell Therapeutics Inc. stock surprise with earnings upside2025 Dividend Review & Real-Time Buy Signal Notifications - Улправда
Will Lineage Cell Therapeutics Inc. stock outperform foreign stocksPortfolio Value Report & Stepwise Entry/Exit Trade Alerts - DonanımHaber
Why Lineage Cell Therapeutics Inc. stock is a must watch in 2025Market Activity Recap & Verified Stock Trade Ideas - DonanımHaber
Buybacks Report: How rising interest rates impact Lineage Cell Therapeutics Inc. stockTreasury Yields & Daily Chart Pattern Signals - Улправда
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading 4.7% HigherShould You Buy? - MarketBeat
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading 4.7% Higher – Should You Buy? - Defense World
Aug Shorts: Can Lineage Cell Therapeutics Inc stock withstand sector downturnsPortfolio Gains Report & AI Powered Trade Plan Recommendations - moha.gov.vn
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy - PR Newswire
New Horizons in Cancer Stem Cells Market Exclusive Report with - openPR.com
You might want to take a look at Lineage Cell Therapeutics Inc (LCTX) now - setenews.com
Lineage Cell Therapeutics Q3 2025 Earnings Preview - MSN
Model VAC2Immuno-Oncology for Non-Small Cell Lung Cancer (NSCLC) - Environmental XPRT
How Lineage Cell Therapeutics Inc. stock valuation compares with sector2025 Historical Comparison & Smart Investment Allocation Tips - Newser
What insider trading reveals about Lineage Cell Therapeutics Inc. stockSell Signal & Daily Growth Stock Tips - Newser
Is Lineage Cell Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
How Lineage Cell Therapeutics Inc. stock performs during market turbulence2025 Top Decliners & Safe Swing Trade Setups - Newser
How currency fluctuations impact Lineage Cell Therapeutics Inc. stockPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
Is Lineage Cell Therapeutics Inc. stock safe for risk averse investorsCEO Change & Daily Stock Trend Reports - Newser
Is Lineage Cell Therapeutics Inc. stock attractive for growth ETFsPortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock cheap by valuation metricsJuly 2025 Review & Entry Point Confirmation Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock expanding market penetrationMarket Growth Report & Technical Entry and Exit Alerts - Newser
Will Lineage Cell Therapeutics Inc. stock beat international competitionJuly 2025 Action & Precise Swing Trade Entry Alerts - Newser
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
An analyst sees good growth prospects for Lineage Cell Therapeutics Inc (LCTX) - setenews.com
Is Lineage Cell Therapeutics Inc. stock a buy on weaknessTreasury Yields & Long-Term Growth Plans - Newser
Can Lineage Cell Therapeutics Inc. stock weather global recession2025 Winners & Losers & Technical Pattern Based Buy Signals - Newser
Lineage Cell Therapeutics withdraws CIRM grant application, plans resubmission By Investing.com - Investing.com Australia
Lineage Therap Withdraws CIRM Grant Application - TipRanks
Lineage Cell Therapeutics Inc withdrew CIRM grant application filed in June 2025SEC filing - marketscreener.com
Lineage Cell Therapeutics withdraws CIRM grant application, plans resubmission - Investing.com
Lineage Cell Therapeutics Withdraws CIRM Grant Application - TradingView — Track All Markets
Lineage Cell Therapeutics (LCTX) pulls CIRM CLIN2 grant application, plans OPC1 resubmission - Stock Titan
Published on: 2025-12-10 00:53:07 - earlytimes.in
Does Tuni Textile Mills Limited Have Competitive Moats for LongTerm GrowthDividend Yield Trends & Superior Wealth Strategies - earlytimes.in
Can Shri Jagdamba Polymers Limited Deliver Stable Cash Flow in Market DownturnsRisk-Reward Ratio Analysis & Fast Profit Portfolio Plans - earlytimes.in
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from D. Boral Capital - Defense World
Lineage Cell Therapeutics' (LCTX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Lineage Cell says first OpRegen development milestone under Roche pact achieved - MSN
This trade activity should not be overlooked: Lineage Cell Therapeutics Inc (LCTX) - Setenews
D. Boral Capital Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - Nasdaq
Lineage Cell Therapeutics explores future of dry AMD treatment - Traders Union
LCTX: D. Boral Capital Maintains 'Buy' Rating with $2.00 Price T - GuruFocus
HC Wainwright & Co. Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - Nasdaq
Lineage Cell Therapeutics Inc (LCTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.01%
자본화:
|
볼륨(24시간):